Everything below concerns investigational status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Thorium-232 (232Th) is the main naturally occurring isotope of thorium, with a relative abundance of approximately 99.98%. It has a half-life of 14.0 billion years, which makes it the longest-lived isotope of thorium. It decays by alpha decay to radium-228; its decay chain terminates at stable lead-208. Thorium-232 is a fertile material; it can capture a neutron to form thorium-233, which subsequently undergoes two successive beta decays to uranium-233, which is fissile. As such, it has been used in the thorium fuel cycle in nuclear reactors; various prototype thorium-fueled reactors have been designed. However, as of 2024, thorium fuel has not been widely adopted for commercial-scale nuclear power. In 2025, China reported thorium-to-uranium conversion in an experimental molten-salt reactor.
Salvinorin B ethoxymethyl ether, also known as 2-O-ethoxymethylsalvinorin B (2-EMSB) or as symmetry, is a semi-synthetic analogue of the natural product salvinorin A, the psychoactive chemical in Salvia Divinorum, with a longer duration of action of around 3 hours (compared to less than 30 minutes for salvinorin A), and increased affinity and intrinsic activity at the κ-opioid receptor. Like the related compound herkinorin, 2-EMSB is made from salvinorin B, which is most conveniently made from salvinorin A by deacetylation, as while both salvinorin A and salvinorin B are found in the plant Salvia divinorum, salvinorin A is present in larger quantities. 2-EMSB has an affinity (Ki) of 0.32 nM at the κ-opioid receptor, and around 3,000 times selectivity over the μ- and δ-opioid receptors, making it one of the most potent and selective κ-opioid receptor agonists yet discovered. In animal studies it fully substituted for salvinorin A and the synthetic κ-opioid receptor agonist U-69593, and was active at doses as low as 0.005 mg/kg. Human bioassays found the compound to be active at 50 μg smoked. It has been sold online as an analytical standard.
== Background == Following the signing of the Pretoria Agreement in November 2022, the Interim Regional Administration of Tigray was established as a transitional governing body intended to stabilize the war-torn region. However, implementation of the peace deal stagnated over unresolved constitutional territories (such as Western Tigray), delays in disarming and reintegrating forces, and the failure to return nearly one million internally displaced persons (IDPs). Tensions escalated dramatically in early 2026 when the federal government under Prime Minister Abiy Ahmed unilaterally extended the mandate of the TIA by one year and suspended voting in 30 Tigrayan constituencies, excluding the region from the June 2026 national elections. Concurrently, a severe political fracture emerged within Tigray between TPLF officials and TIA leadership regarding the pace and direction of the post-war transition.
=== United Kingdom === A study in 2004 by the Independent Inquiry into Drug Testing at Work found that attempts by employers to force employees to take drug tests could potentially be challenged as a violation of privacy under the Human Rights Act 1998 and Article 8 of the European Convention of Human Rights. However, this does not apply to industries where drug testing is a matter of personal and public safety or security rather than productivity.
Marc Laidlaw is an American writer. Between 1997 and 2016, he was a writer for the video game company Valve, where he worked on the Half-Life and Portal series. Before joining Valve, Laidlaw was a novelist working in fantasy and horror. In 1996 he won the International Horror Guild Award for his novel The 37th Mandala. In 2025, Laidlaw's 1983 short story "400 Boys" was adapted as an episode of the Netflix series Love, Death & Robots.
Sources: en.wikipedia.org
=== Multi-locus sequence typing === Multilocus sequence typing (MLST) is the sequencing of numerous loci to diagnose an organism by comparing DNA sequences to a database of known organisms. This method is often used to compare isolates or strains of the same species to see if they are indistinguishable or different from each other. This is common for tracking food-borne illnesses and public health outbreaks. Most MLST assays are published in scientific journals so consistent methods are used worldwide. There are also public databases available for tracking and comparisons.
Following the guidelines of the European institutions, the "adjustment" policy was accompanied by the introduction of three important "structural reforms": the Labor Reform of September 2010 with the purpose of making it more "flexible"; the new law on pensions approved in June 2011 which raised the retirement age from 65 to 67; and the Royal Decree Law, also of June 2011, which "made more flexible" the collective bargaining system. It also raised the general VAT rate from 16 to 18%. The turn in economic policy caused the government to break with the unions who called a general strike for September 29, 2010, the first since Zapatero was in power. Despite all the measures adopted by the government, the risk premium on Spanish debt continued to rise and in the summer of 2011 the situation became unsustainable. Then the European Central Bank decided to act by buying Spanish public debt – and that of other countries with problems, such as Italy— but in exchange it demanded new "structural reforms". The response of Rodríguez Zapatero's government was to proceed quickly with the reform of Article 135 of the Constitution, in which it had the immediate support of the People's Party, to establish the commitment of the State and the autonomous communities not to "incur a structural deficit that exceeds the margins established, where appropriate, by the European Union for its Member States".
=== Parasites === Emus can suffer from both external and internal parasites, but under farmed conditions are more parasite-free than ostriches or rheas. External parasites include the louse Dahlemhornia asymmetrica and various other lice, ticks, mites and flies. Chicks sometimes suffer from intestinal tract infections caused by coccidian protozoa, and the nematode Trichostrongylus tenuis infects the emu as well as a wide range of other birds, causing haemorrhagic diarrhoea. Other nematodes are found in the trachea and bronchi; Syngamus trachea causing haemorrhagic tracheitis and Cyathostoma variegatum causing serious respiratory problems in juveniles.
A number of these women would go on to join a class action lawsuit, Madrigal v. Quilligan, discussed below. These Mexican and Mexican-American women were given the stereotype as "hyper-fertile" and were believed to lack the knowledge of birth control methods due to the high numbers of teen pregnancies occurring within their community. At the Hospital of LA County+USC, coercive sterilization was justified as it was an attempt to control the birthrate of these women. In 1998 the US government performed a census and multiyear analysis of Latino births and found the women of Mexican origin displayed the highest rate of childbirth compared to other Latina women. From these statistics, the "Save our State" campaign arose and worked to enforce more eugenic sterilization of these women. In 1973 an investigation by progressive anti-sterilization advocacy groups discovered the stories of Mary Alice's and Minnie Lee Relf's sterilization. This story was released by the Southern Poverty Law Center and led to the discovery of 16 thousand women and 8,000 men being sterilized using federal funds in 1972. In addition to this finding, they found more than three hundred of these patients were under the legal age of 21. Following this discovery and exposure, in 1977 Mexican-American began coming forth to file lawsuits in relation to coercive sterilization they faced while in labor. In 1979 a bill to repeal the eugenics laws passed that legalized sterilization was proposed to the legislature in California.
Sources: en.wikipedia.org
== History == Carbamazepine was discovered by chemist Walter Schindler at J.R. Geigy AG (now part of Novartis) in Basel, Switzerland, in 1953. It was first marketed as a drug to treat epilepsy in Switzerland in 1963 under the brand name Tegretol; its use for trigeminal neuralgia (formerly known as tic douloureux) was introduced at the same time. It has been used as an anticonvulsant and antiepileptic in the United Kingdom since 1965, and has been approved in the United States since 1968. Carbamazepine was studied for bipolar disorder throughout the 1970s.
cell compartmentalization The subdivision of the interior of a cell into distinct, usually membrane-bound compartments, including the nucleus and organelles (endoplasmic reticulum, mitochondria, chloroplasts, intracellular vesicles, etc.), a defining feature of the Eukarya.
=== Late onset === In milder (or partial) urea cycle enzyme deficiencies, ammonia accumulation may be triggered by illness or stress at almost any time of life, resulting in multiple mild elevations of plasma ammonia concentration [Bourrier et al. 1988]. Patients with partial enzyme deficiencies may have a delay of symptoms for months or years. Indicators that you maybe suffering from OTC deficiency or a urea cycle disorder include "episodes of delirium, erratic behavior, or reduced consciousness, headaches, vomiting, aversion to foods high in protein, and seizures."
==== Remote monitoring ==== Spectrometers on earth-observation satellites allow monitoring of formaldehyde in the troposphere. Using ultraviolet–visible spectroscopy, instruments detect absorption features in sunlight reflected by the Earth and use differential optical absorption spectroscopy to calculate vertical column densities. Near-global maps of tropospheric HCHO with daily coverage and kilometer-scale spatial resolution come from the OMI instrument on Aura, the GOME-2 instrument on MetOp, and the newer TROPOMI sensor on Sentinel-5P. Regional maps with hourly coverage over North America are available from the TEMPO instrument on Intelsat 40e. The close coupling between isoprene and formaldehyde has been widely used in top-down approaches that derive regional and global isoprene emissions from satellite measurements of tropospheric formaldehyde columns. These studies provide important constraints on the magnitude and spatial pattern of biogenic isoprene emissions. Processes in the upper atmosphere contribute more than 80% of the total formaldehyde in the environment. Formaldehyde is an intermediate in the oxidation (or combustion) of methane and other carbon compounds from sources such as forest fires, automobile exhaust, and tobacco smoke. When produced in the atmosphere by the action of sunlight and oxygen on atmospheric methane and other hydrocarbons, it becomes part of smog. Formaldehyde has also been detected in outer space.
=== Anion-exchange resins === Formula: R-OH basic Anion resins may be either strongly or weakly basic. Strongly basic anion resins maintain their negative charge across a wide pH range, whereas weakly basic anion resins are neutralized at higher pH levels. Weakly basic resins do not maintain their charge at a high pH because they undergo deprotonation. They do, however, offer excellent mechanical and chemical stability. This, combined with a high rate of ion exchange, make weakly base anion resins well suited for the organic salts. For anion resins, regeneration typically involves treatment of the resin with a strongly basic solution, e.g. aqueous sodium hydroxide. Regenerant strength (1–4 % NaOH) and contact time must be optimized to avoid excessive osmotic stress on the polymer matrix. These anion resins can be regenerated by flushing them with a caustic solution (typically 1–4 % NaOH as mentioned before). During regeneration process, the regenerant chemical is passed through the resin, and trapped negative ions are flushed out, renewing the resin exchange capacity.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.